| Date | Time | Source | |
| 06/19/2013 | 10:52AM | DJN | UPDATE: Bristol, AstraZeneca Diabetes Drug Fails to Cut Heart Risk
--Onglyza had comparable cardiovascular safety to placebo in large trial --Results unlikely to give hoped-for lift to market for diabetes pills --Merck is conducting similar study of its blockbuster Januvia (Adds details and background throughout.) By Peter Loftus A diabetes drug co-marketed by Bristol-Myers Squibb Co... More...>> |
| 06/18/2013 | 7:10AM | DJN | RedHill Biopharma: FDA Sets Feb. 3 Goal Date to Review Generic Maxalt Application
By Melodie Warner RedHill Biopharma Ltd. (RDHL, RDHL.TV) and IntelGenx Technologies Corp. (IGXT, IGX.V) said the U.S. Food and Drug Administration accepted their new drug application for the experimental acute migraine treatment RHB-103 and has set a Feb. 3 target date to complete its review. RHB-103, a dissolvable strip... More...>> |
| 06/14/2013 | 3:30PM | DJN | Merck R&D Job Cuts Strip Layer of Senior Management
Merck & Co. is cutting jobs and stripping a layer of senior management from its research-and-development arm, as its new chief seeks to turnaround a unit he said is marked by "the complexity of our organizational design." Roger Perlmutter, who took the helm of Merck's laboratories in April, eliminated "franchise head... More...>> |
| 06/14/2013 | 1:58PM | DJN | Merck Shakes Up Drug Research Unit, Plans Job Cuts
By Peter Loftus Merck & Co. (MRK) is making changes in its research-and-development arm--including job cuts and a new structure--two months after the drug maker hired a new executive to lead the unit. "The changes will involve a reduction in force, some more immediate and some over time," Merck spokesman Steven Cragle... More...>> |
| 06/14/2013 | 1:58PM | DJN | Merck Shakes Up Drug Research Unit, Plans Job Cuts
By Peter Loftus Merck & Co. (MRK) is making changes in its research-and-development arm--including job cuts and a new structure--two months after the drug maker hired a new executive to lead the unit. "The changes will involve a reduction in force, some more immediate and some over time," Merck spokesman Steven Cragle... More...>> |
| 06/13/2013 | 6:20PM | DJN | UPDATE: Lilly Ends Alzheimer's Drug Study On Safety Concern
--Lilly stops study of Alzheimer's drug, cites abnormal liver tests in some patients --Lilly doesn't believe liver tests are related to drug's mechanism of action --Latest in series of research setbacks in industry's hunt for better Alzheimer's treatment (Adds details and background throughout.) By Peter Loftus Eli Lilly... More...>> |
| 06/12/2013 | 2:23PM | DJN | UPDATE: Merck Backs Call for Independent Review of Diabetes Treatments
--Bristol-Myers, AstraZeneca also support American Diabetes Association's proposal --Planned overview comes months after U.S. regulators open review of some treatments --Companies aim to cooperate on logistics (Adds details from Bristol-Myers and AstraZeneca in paragraphs three through five, share prices in final paragraph... More...>> |
| 06/12/2013 | 9:21AM | DJN | Merck Backs Call for Independent Review of Diabetes Treatments
By Tess Stynes Merck & Co. (MRK) said the pharmaceutical company welcomes this week's call by the American Diabetes Association for an independent review of data about the safety of some diabetes treatments--including Merck's Januvia--which comes several months after U.S. regulators also opened a review of several... More...>> |
| 06/12/2013 | 8:00AM | BW | Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines
Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Association’s (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors... More...>> |
| 06/12/2013 | 8:00AM | BW | Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines
Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Association’s (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors... More...>> |
| 06/06/2013 | 5:56PM | DJN | UPDATE: Immunotherapy Cancer Drug Race Speeds Up After Medical Meeting
--Bristol-Myers, Merck and Roche developing promising class of cancer drugs --Further studies will clarify drugs' benefits and risks --Analysts say drugs have multi-billion-dollar market potential (Adds details about Merck study plans.) By Peter Loftus A promising new class of experimental drugs that unleash the body's... More...>> |
| 06/06/2013 | 10:13AM | DJN | Immunotherapy Cancer Drug Race Speeds Up After Medical Meeting
By Peter Loftus A promising new class of experimental drugs that unleash the body's immune system against tumors stole the show at a just-concluded meeting of cancer doctors. Now the focus turns to additional studies that may show whether the relatively high rates of tumor shrinkage triggered by the drugs in early-stage... More...>> |
| 06/03/2013 | 4:55PM | DJN | MARKET SNAPSHOT: U.S. Stocks Make Late Leap In Fed-inspired Trade
By Kate Gibson, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks rallied on Monday, bouncing back from weekly losses, as investors gauged the impact of disappointing factory data on potential quantitative-easing moves by the Federal Reserve. In an interview on Bloomberg Television, Federal Reserve Bank of Atlanta President... More...>> |
| 06/03/2013 | 4:46PM | DJN | MARKET SNAPSHOT: U.S. Stocks Make Late Leap In Fed-inspired Trade
By Kate Gibson, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks rallied on Monday, bouncing back from weekly losses, as investors gauged the impact of disappointing factory data on potential quantitative-easing moves by the Federal Reserve. In an interview on Bloomberg Television, Federal Reserve Bank of Atlanta President... More...>> |
| 06/03/2013 | 4:05PM | DJN | MARKET SNAPSHOT: U.S. Stocks Mostly Up In Fed-inspired Trade
By Kate Gibson, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks traded mostly higher on Monday, bouncing back from weekly losses, with investors weighing the impact of disappointing manufacturing data on potential quantitative-easing moves by the Federal Reserve. "We can now say with even more confidence that there is... More...>> |
| 06/03/2013 | 3:14PM | DJN | MARKET SNAPSHOT: U.S. Stocks Mixed After Weak Factory Data
By Kate Gibson, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks veered between gains and losses on Monday as investors weighed the impact of a disappointing U.S. manufacturing report on potential quantitative-easing moves by the Federal Reserve. "We can now say with even more confidence that there is literally zero chance... More...>> |
| 06/03/2013 | 2:37PM | DJN | What Makes a Breakthrough Cancer Drug in the Eyes of the FDA
By Peter Loftus CHICAGO--In the eyes of Richard Pazdur, a breakthrough cancer drug should be "transformative." His view is important because Dr. Pazdur is the head of the U.S. Food and Drug Administration's office of hematology and oncology products, which helps decide whether experimental cancer drugs are sufficiently... More...>> |
| 06/03/2013 | 2:06PM | DJN | MARKET SNAPSHOT: U.S. Stocks Mainly Lower On Weak Data; Dow Gains
By Kate Gibson, MarketWatch NEW YORK (MarketWatch) -- U.S. stocks traded mostly lower on Monday as investors weighed the impact of a disappointing U.S. manufacturing report on potential quantitative-easing moves by the Federal Reserve. "We can now say with even more confidence that there is literally zero chance the Fed... More...>> |
| 06/02/2013 | 3:21PM | DJN | UPDATE: Merck Drug Shrinks Tumors in Melanoma Patients in Study
--Merck's experimental lambrolizumab shrinks tumors in 38% of melanoma patients in study --Merck to study drug in late-stage trials in melanoma and lung cancer --Similar drug from Bristol-Myers also shows promise in studies (Adds updated data for Bristol-Myers' drug in 10th paragraph.) By Peter Loftus CHICAGO--An experimental... More...>> |
| 06/02/2013 | 11:45AM | DJN | Merck Drug Shrinks Tumors in Melanoma Patients in Study
By Peter Loftus CHICAGO--An experimental Merck & Co. (MRK) drug shrank tumors in a promising number of skin-cancer patients in a clinical trial--the latest milestone for an emerging crop of therapies that unleash the body's immune system to fight cancer. Merck said Sunday it plans to start late-stage clinical trials... More...>> |
